Pembrolizumab Shows Further Promise for Melanoma In a phase III clinical trial, pembrolizumab yielded a 75.4 percent recurrence-free survival rate after 12 months among patients whose stage III melanoma tumors had been fully resected. by Brad Jones Forward Look Tackling Drug Resistance Researchers are studing new ways to keep treatments working longer. by Stephen Ornes Survivor Profile Living in the Here and Now A metastatic melanoma survivor is hopeful but realistic as new treatments become available. by Jenny Song Forward Look Cancer Immunotherapies Continue to Make Headway Drugs that harness the power of the immune system gain new approvals. by Alexandra Goho Survivor Profile Knowing Her Options When Christina McEvoy was diagnosed with stage IV melanoma, she took the reins of her care, traveling more than 600 miles for treatment and returning home to help other melanoma survivors. by Melissa Davlin First Person Keeping Sight of Hope A survivor keeps an eye on what's ahead after a rare cancer diagnosis. by Sue Russell Cancer Talk Canine Comfort Studies investigate whether visits from therapy dogs can increase the well-being of cancer patients and caregivers. by Jen Tota McGivney Will Right to Try Increase Access to Experimental Treatments? The recently passed Right to Try Act is meant to provide patients with greater access to experimental therapies. Patient advocates are divided on whether the law will benefit patients. by Marci A. Landsmann What Older Patients Value Many older adults with cancer place more importance on maintaining their independence and cognitive abilities than on living as long as possible. by Cheryl Platzman Weinstock Omitting Obesity Many cancer clinical trials do not track what proportion of enrolled patients are obese, a study finds. These patients may be underrepresented in research. by Cici Zhang More Posts